https://images.app.goo.gl/BBNsE5dgrFX731s17
Gemovac-OM, an mRNA-based booster vaccination designed specifically for Omicron and created by Gennova utilising its own platform technology, was introduced by Union Minister Jitendra Singh on Saturday.
The Department of Biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC) have provided financing to Gennova, which has created India’s first mRNA vaccine utilising indigenous platform technology, according to the Ministry of Science & Technology.
Recently, the vaccine received approval for Emergency Use Authorization (EUA) from the office of the Drug Control General of India (DCGI).
“I take tremendous delight in DBT continuing to meet its purpose of fostering technology-driven entrepreneurship by developing this homegrown mRNA-platform technology. In keeping with the Prime Minister’s vision of Aatmanirbharta, we have always backed technology-driven innovation in the construction of a “future-ready” technological platform, according to Jitendra Singh.
Gemovac-OM is the sixth vaccine created with assistance from Mission Covid Suraksha, a programme that DBT and BIRAC are implementing as part of the Atmanirbhar Bharat 3.0 package to hasten the development of Indian covid-19 vaccines.
The development of the world’s first DNA vaccine for COVID-19 and the nation’s first mRNA vaccine, as well as candidates for intranasal vaccines and a subunit vaccine against COVID-19, were among the major accomplishments of the Mission Covid Suraksha within a year of its implementation, according to the minister.
In a relatively short amount of time, he claimed, different vaccines may be produced using this “future-ready” technological platform.
“Stable investments made by the government have strengthened the startup and business environment, which has actually accelerated our response to the COVID-19 pandemic mitigation. I applaud DBT and BIRAC for once again carrying out their purpose by fostering technology-driven entrepreneurship via the development of this homegrown mRNA-platform technology,” Singh continued.
Due to its thermostability, GEMCOVAC-OM does not require the ultra-cold chain infrastructure that is necessary for other mRNA-based vaccines that have been authorised.
“This invention makes last mile deployment in our nation simple. The ability of this vaccine to be provided without a needle injection makes it unique, according to Singh, who also stated that the current infrastructure of the supply chain is adequate for its deployment.
A needle-free injection device system is used to administer the vaccine intradermally, and research participants’ immune responses were noticeably enhanced by this method. The clinical outcome shows that variant-specific vaccinations are required to elicit the optimal immune response.
